The point is you proposed, to my knowledge, a new indication for leronlimab without an explanation as to what the mechanism of action might be for treating severe cases of influenza and how you would propose that we go about determining this.

I also “wonder,” as you say, how one could identify who would need leronlimab upon presentation. Other than age, comorbidities, vaccination status, etc., which are just broad indicators as to the likely course of an influenza infection, I don’t know how one would do this. It’s in the realm of clinical judgement, which lends itself to qualitative analysis not quantitative.

The existing literature suggests caution. Does the literature prove that leronlimab would definitively be useful or dangerous in severe cases of influenza? No. So far, leronlimab seems to not effect normal immune functions; however, a population of 800 is still small and I have no idea if any of these patients experienced an influenza infection while taking leronlimab. It would be very interesting to know how they faired, if any did contract influenza. With 800 patients, with challenged immune systems, one would think that surely some contracted influenza during a study.

It would appear, again, however, that based upon existing literature, we should be cautious in proposing this as a specific indication.